Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention in Germany

Novel pharmaceutical treatments reducing cardiovascular events in dyslipidaemia patients must demonstrate clinical efficacy and cost-effectiveness to promote long-term adoption by patients, physicians, and insurers.

Saved in:

Bibliographic Details
Main Authors:	Michaeli, Daniel (Author) , Michaeli, Julia (Author) , Boch, Tobias (Author) , Michaeli, Christoph T. (Author)
Format:	Article (Journal)
Language:	English
Published:	August 2023
In:	Cardiovascular drugs and therapy Year: 2023, Volume: 37, Issue: 4, Pages: 683-694
ISSN:	1573-7241
DOI:	10.1007/s10557-021-07310-y
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s10557-021-07310-y Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s10557-021-07310-y
Author Notes:	Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Thomas Michaeli

Description
Summary:	Novel pharmaceutical treatments reducing cardiovascular events in dyslipidaemia patients must demonstrate clinical efficacy and cost-effectiveness to promote long-term adoption by patients, physicians, and insurers.
Item Description:	Online veröffentlicht: 11. Januar 2022 Gesehen am 09.07.2024
Physical Description:	Online Resource
ISSN:	1573-7241
DOI:	10.1007/s10557-021-07310-y